# Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer

> **NCT03344172** · PHASE2 · TERMINATED · sponsor: **Nathan Bahary, MD** · enrollment: 32 (actual)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab
- **DRUG:** Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine

## Key facts

- **NCT ID:** NCT03344172
- **Lead sponsor:** Nathan Bahary, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-13
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Suspected Serious Adverse Events related to treatment
- **Last updated:** 2020-05-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344172, "Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03344172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*